Home › Uveal Melanoma › California
Uveal Melanoma clinical trials in California
7 studies for Uveal Melanoma are looking for participants at sites in California.
Cities in California
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- UCLA Medical Center, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07804186Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- UCLA Medical Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Stanford Cancer Institute, Stanford
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- UCSD Moores Cancer Center, La Jolla
- Jules Stein Eye Institute, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- UC San Diego Moores Cancer Center, La Jolla
- The Angeles Clinic and Research Institute, Los Angeles
- University of California Los Angeles, Los Angeles
- and 1 more
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
- City of Hope, Duarte
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
- Stanford Cancer Institute, Stanford
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 17, 2026 · NCT04119024Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
- The Angeles Clinic and Research Institute, Los Angeles
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 4, 2025 · NCT06121180From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.